创始人
王喆 博士
创始人、董事长
王喆博士师从诺贝尔化学奖得主 E.J. Corey教授，从事药物开发研究工作20余年，有领导从立项到药物上市的完整产业链经验，在抗感染、抗病毒及抗癌新药研发领域有极深的造诣与卓越成就。
Founder
Dr. Zhe WANG
Founder, chairman
Dr. Zhe WANG studied under Prof. E.J. Corey, a Nobel laureate in chemistry.
With more than 20 years engaged in drug research and development, Dr. Zhe WANG has full experience of leading drug development from project initiation to drug launch. He has profound attainments and outstanding achievements in the field of new drug of anti-infection, anti-virus and anti-cancer.
研发体系
长森药业聚焦自身免疫疾病、肿瘤免疫治疗、抗病毒等领域的创新药研发与产业化，管线产品临床评估指标均达到国际领先水平，有望成为相关领域的重大突破（FIC，first in class）。
长森药业专注具有自主知识产权及国际领先水平的创新药物的开发和医学转化，通过合作开发、Licensing Out等形式，积极参与国际竞争，解决尚未满足的临床需求。
R&D
Longwood Biopharma is focusing on the development and industrialization of innovative drugs in the fields of autoimmune diseases, tumor immunotherapy and anti-virus. With world-class performance in clinical evaluation, our pipelines are expected to become a major breakthrough in related fields (FIC, first in class).
Longwood Biopharma focuses on the development and medical translation of world-class innovative drugs with independent IPR, and actively participates in international competition through co-development and licensing-out to address unmet clinical needs.
新闻资讯
【长森快讯】长森药业荣获“创客上海2026”三等奖
近日，长森药业自主研发的双功能双靶点乙肝一类新药LW231在“创客上海2026”暨第十一届“创客中国”上海中小企业创新创业大赛总决赛中脱颖而出，荣获三等奖...
【长森快讯】新一代口服高选择性JAK1抑制剂 LW402完成白癜风II期临床首例患者入组
近日，长森药业自主研发的高选择性JAK1抑制剂LW402成功完成白癜风II期临床首例患者入组。
【长森快讯】新一代口服高选择性JAK1抑制剂 LW402完成特应性皮炎（AD）III期临床首例患者入组
近日，长森药业自主研发的高选择性JAK1抑制剂LW402成功完成特应性皮炎（AD）III期临床首例患者入组。
News
【LWBP NEWS】LWBP Wins Third Prize at “Maker Shanghai 2026”
Recently, LW231, a bi-functional, dual-target drug for complete cure of Hepatitis B, independently developed by LWBP, stood out among more than 1,000 participants and won the third prize of “Maker Shanghai 2026” and the 11th “Maker in China” Shanghai SME Innovation and Entrepreneurship Competition......
【LWBP NEWS】Next-Generation Highly Selective JAK1 Inhibitor LW402 Enrolls First Patient in Phase 2 Clinical Trial for Vitiligo
Recently, the multicenter, randomized, double-blind, placebo-controlled Phase 2 clinical trial of oral LW402 tablets for the evaluation of efficacy and safety in patients with non-segmental vitiligo has successfully enrolled its first patient.
【LWBP NEWS】Next-Generation Highly Selective JAK1 Inhibitor LW402 Enrolls First Patient in Phase 3 Clinical Trail for Atopic Dermatitis (AD)
Recently, the multicenter, randomized, double-blind, placebo-controlled Phase 3 clinical trial of LW402 for the evaluation of efficacy and safety in patients with moderate-to-severe atopic dermatitis （AD） has successfully enrolled its first patient.
